Despite the existence of the statutory early cancer detection program in Germany and the removal of financial barriers, which is frequently reported in the literature to be the main obstacle in screening, uptake of colorectal cancer screening remains quite low. The campaign for colorectal cancer screening in German companies reported in this article started in 2010. It was initiated because of the low compliance with opportunistic public colorectal cancer screening efforts. Its goal is to improve participation by offering an organized screening program using a simple test (FIT).
go from "overstating the benefits" to "downstream effects and potential harms". Overall, opponents argue that most people undergoing screening are neither identified as having cancer nor protected from its developing (8) .
A screening test must be well accepted.
However, uptake of screening could be improved by offering methods that are more acceptable. Adler et al. (2014) reported that of the 63% who refused colonoscopy, 97% accepted an alternative non-invasive screening method (FOBT) or a minimally invasive technique (blood test) (9) . This refers to both men and women. Despite the fact that colonoscopy is the "golden standard" screening tool for colorectal cancer and its precursor lesions, its actual benefit is diminished due to low uptake (10) .
In recent years, the FIT (fecal immunochemical test), which is also known as iFOBT (immune fecal occult blood test), has emerged as an alternative to the guaiacbased test. Despite the lack of evidence of its effect on CRC mortality, it has shown better sensitivity for detection of carcinomas and adenomas, and acceptable specificity (11) (12) (13) over gFOBT, whereby the latter was shown to reduce mortality in a large meta-analysis (14) .
FIT has also been demonstrated to be more acceptable to the target population than gFOBT. In randomized studies, the response to invitations offering FIT screening was found to be up to 16% higher than that for gFOBT. This was attributed to the more acceptable collection method, the smaller number of fecal samples, and the lack of dietary restrictions (15) (16) (17) (18) (19) . In addition, due to its quantitative nature, FIT hemoglobin cut-off levels can be tailored to the risk population and colonoscopy resources available.
In a randomized control trial (RCT) comparing FIT to colonoscopy as a primary screening tool, one-time FIT was non-inferior to colonoscopy in the detection of colorectal cancer, but had lower sensitivity for adenomas. This was viewed by the author to be a possible disadvantage in terms of CRC prevention as a goal of screening but also as a potential advantage in terms of reducing overdiagnosis and the accompanying unnecessary colonoscopy costs and complications. The difference in mortality will be assessed at the end of the ongoing 10-year trial. Overall, the colonoscopy complication rates were significantly lower in the FIT group than in the colonoscopy group, which is an important ethical consideration in terms of the "first do no harm" principle (10) . The point has also been raised that large scale implementation of the FIT as a screening method may improve health care equity (20) .
Various studies have found that participation in fecal immunochemical testing is higher than in colonoscopy procedures, which could improve the overall diagnostic yield beyond the mere sensitivity and specificity of the test (9, 10, 21 advanced adenomas and carcinomas expressed as positive likelihood ratio.
Methods
An offer for company employees to have an FIT 
Laboratory Analysis
All test kits were analyzed at the Care diagnostica laboratory on the day they were received using immoCARE-C tests with a cut-off value of 50 ng Hb/ml buffer.
Statistical Analysis
Return rates were monitored for the duration of 
Results
We received a response from 444,888 individuals during the time of this study. 50% of the completed kits were returned within the first 24 days and 90% were returned within 81 days of when they were ordered ( Figure 2 ).
Of the total kits analyzed, 5.6% gave a positive result. The test positivity rates were higher for men, except in the below 40 age groups (Figure 3 ) (p-value for total difference <0.0001).
The number of FIT requests, return rates, and the number and percentage of those who tested positive is shown in Table 1 by age and sex.
Those who returned the kits within 20 days were more likely to have a positive result than those who took longer to return them, with average positivity rates of 6% and 5.4%, respectively (p-value < 0.001). The positive likelihood ratio estimates for those between the ages of 55-74 who had colonoscopy forms available (n= 498) are shown in Table 3 for carcinomas and adenomas.
Discussion
CRC is one of the leading causes of cancerrelated deaths in men and women in Germany as well as in the United States. However, routine testing can actually prevent many cases of CRC or find it at an early stage, when treatment is most likely to be successful.
"The best test is the one that gets done" (25) We used the prevalence data from another study conducted in Germany to calculate the LR+, which did not report the age distribution of the participants.
Therefore, there may be some discrepancy with our group's prevalence, even though our reported LR+ was similar to previously published ones. This sample is not representative of the corresponding age group in the general population because it does not include retirees or those working outside the scope of company employment, although many companies did extend their offer to former employees and employees' partners.
Talking with peers and family has been reported to be a key factor in influencing uptake of CRC screening (26, 28) , thus the influence of colleagues may have a positive effect on participation. However, this initiative from the participating companies offers a diagnostic tool to their employees to prevent colon cancer, which caused 15.8 and 23.3 lost workdays/1000 employees in 2012 for both women and men (27) .
Conclusions
Offering CRC screening in companies may be an effective way of increasing uptake in the target population. Differences in the test performance between men and women need further evaluation. For the draft of the manuscript, the authors from outside the laboratory only took note of descriptive numbers and rates for further statistical analysis. No data sets, either anonymized or encoded, were referred.
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